Literature DB >> 33723286

Pancancer survival analysis of cancer hallmark genes.

Ádám Nagy1,2, Gyöngyi Munkácsy1, Balázs Győrffy3,4.   

Abstract

Cancer hallmark genes are responsible for the most essential phenotypic characteristics of malignant transformation and progression. In this study, our aim was to estimate the prognostic effect of the established cancer hallmark genes in multiple distinct cancer types. RNA-seq HTSeq counts and survival data from 26 different tumor types were acquired from the TCGA repository. DESeq was used for normalization. Correlations between gene expression and survival were computed using the Cox proportional hazards regression and by plotting Kaplan-Meier survival plots. The false discovery rate was calculated to correct for multiple hypothesis testing. Signatures based on genes involved in genome instability and invasion reached significance in most individual cancer types. Thyroid and glioblastoma were independent of hallmark genes (61 and 54 genes significant, respectively), while renal clear cell cancer and low grade gliomas harbored the most prognostic changes (403 and 419 genes significant, respectively). The eight genes with the highest significance included BRCA1 (genome instability, HR 4.26, p < 1E-16), RUNX1 (sustaining proliferative signaling, HR 2.96, p = 3.1E-10) and SERPINE1 (inducing angiogenesis, HR 3.36, p = 1.5E-12) in low grade glioma, CDK1 (cell death resistance, HR = 5.67, p = 2.1E-10) in kidney papillary carcinoma, E2F1 (tumor suppressor, HR 0.38, p = 2.4E-05) and EREG (enabling replicative immortality, HR 3.23, p = 2.1E-07) in cervical cancer, FBP1 (deregulation of cellular energetics, HR 0.45, p = 2.8E-07) in kidney renal clear cell carcinoma and MYC (invasion and metastasis, HR 1.81, p = 5.8E-05) in bladder cancer. We observed unexpected heterogeneity and tissue specificity when correlating cancer hallmark genes and survival. These results will help to prioritize future targeted therapy development in different types of solid tumors.

Entities:  

Year:  2021        PMID: 33723286     DOI: 10.1038/s41598-021-84787-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  29 in total

1.  Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype.

Authors:  K Nosho; T Kawasaki; A T Chan; M Ohnishi; Y Suemoto; G J Kirkner; C S Fuchs; S Ogino
Journal:  Histopathology       Date:  2008-11       Impact factor: 5.087

2.  Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.

Authors:  Li Ding; Matthew H Bailey; Eduard Porta-Pardo; Vesteinn Thorsson; Antonio Colaprico; Denis Bertrand; David L Gibbs; Amila Weerasinghe; Kuan-Lin Huang; Collin Tokheim; Isidro Cortés-Ciriano; Reyka Jayasinghe; Feng Chen; Lihua Yu; Sam Sun; Catharina Olsen; Jaegil Kim; Alison M Taylor; Andrew D Cherniack; Rehan Akbani; Chayaporn Suphavilai; Niranjan Nagarajan; Joshua M Stuart; Gordon B Mills; Matthew A Wyczalkowski; Benjamin G Vincent; Carolyn M Hutter; Jean Claude Zenklusen; Katherine A Hoadley; Michael C Wendl; Llya Shmulevich; Alexander J Lazar; David A Wheeler; Gad Getz
Journal:  Cell       Date:  2018-04-05       Impact factor: 41.582

3.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

Authors:  Yixin Wang; Jan G M Klijn; Yi Zhang; Anieta M Sieuwerts; Maxime P Look; Fei Yang; Dmitri Talantov; Mieke Timmermans; Marion E Meijer-van Gelder; Jack Yu; Tim Jatkoe; Els M J J Berns; David Atkins; John A Foekens
Journal:  Lancet       Date:  2005 Feb 19-25       Impact factor: 79.321

4.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

5.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

6.  Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.

Authors:  B Fisher; C Redmond; A Brown; D L Wickerham; N Wolmark; J Allegra; G Escher; M Lippman; E Savlov; J Wittliff
Journal:  J Clin Oncol       Date:  1983-04       Impact factor: 44.544

Review 7.  Development of the 21-gene assay and its application in clinical practice and clinical trials.

Authors:  Joseph A Sparano; Soonmyung Paik
Journal:  J Clin Oncol       Date:  2008-02-10       Impact factor: 44.544

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 9.  PanCancer insights from The Cancer Genome Atlas: the pathologist's perspective.

Authors:  Lee Ad Cooper; Elizabeth G Demicco; Joel H Saltz; Reid T Powell; Arvind Rao; Alexander J Lazar
Journal:  J Pathol       Date:  2018-02-22       Impact factor: 7.996

10.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.

Authors:  Christina Curtis; Sohrab P Shah; Suet-Feung Chin; Gulisa Turashvili; Oscar M Rueda; Mark J Dunning; Doug Speed; Andy G Lynch; Shamith Samarajiwa; Yinyin Yuan; Stefan Gräf; Gavin Ha; Gholamreza Haffari; Ali Bashashati; Roslin Russell; Steven McKinney; Anita Langerød; Andrew Green; Elena Provenzano; Gordon Wishart; Sarah Pinder; Peter Watson; Florian Markowetz; Leigh Murphy; Ian Ellis; Arnie Purushotham; Anne-Lise Børresen-Dale; James D Brenton; Simon Tavaré; Carlos Caldas; Samuel Aparicio
Journal:  Nature       Date:  2012-04-18       Impact factor: 49.962

View more
  221 in total

1.  Spatial Mapping and Immunomodulatory Role of the OX40/OX40L Pathway in Human Non-Small Cell Lung Cancer.

Authors:  Angelo Porciuncula; Micaela Morgado; Richa Gupta; Kostas Syrigos; Robert Meehan; Sima J Zacharek; Joshua P Frederick; Kurt A Schalper
Journal:  Clin Cancer Res       Date:  2021-09-13       Impact factor: 12.531

2.  High P2X6 receptor expression in human bladder cancer predicts good survival prognosis.

Authors:  Fabrícia Dietrich; Angélica Regina Cappellari; Eduardo Cremonese Filippi-Chiela; Patrícia Boni de Paula; Julia Brandt de Souza; Stefano Walter Agatti; Roberta Andrejew; Rafael Roesler; Fernanda Bueno Morrone; Ana Maria Oliveira Battastini
Journal:  Mol Cell Biochem       Date:  2022-04-16       Impact factor: 3.396

3.  AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity.

Authors:  Emiliano Maiani; Giacomo Milletti; Francesca Nazio; Søs Grønbæk Holdgaard; Jirina Bartkova; Salvatore Rizza; Valentina Cianfanelli; Mar Lorente; Daniele Simoneschi; Miriam Di Marco; Pasquale D'Acunzo; Luca Di Leo; Rikke Rasmussen; Costanza Montagna; Marilena Raciti; Cristiano De Stefanis; Estibaliz Gabicagogeascoa; Gergely Rona; Nélida Salvador; Emanuela Pupo; Joanna Maria Merchut-Maya; Colin J Daniel; Marianna Carinci; Valeriana Cesarini; Alfie O'sullivan; Yeon-Tae Jeong; Matteo Bordi; Francesco Russo; Silvia Campello; Angela Gallo; Giuseppe Filomeni; Letizia Lanzetti; Rosalie C Sears; Petra Hamerlik; Armando Bartolazzi; Robert E Hynds; David R Pearce; Charles Swanton; Michele Pagano; Guillermo Velasco; Elena Papaleo; Daniela De Zio; Apolinar Maya-Mendoza; Franco Locatelli; Jiri Bartek; Francesco Cecconi
Journal:  Nature       Date:  2021-04-14       Impact factor: 49.962

4.  Transmembrane adaptor protein PAG is a mediator of PD-1 inhibitory signaling in human T cells.

Authors:  Marianne Strazza; Inbar Azoulay-Alfaguter; Michael Peled; Kieran Adam; Adam Mor
Journal:  Commun Biol       Date:  2021-06-03

5.  Decreased prostasin expression is associated with aggressiveness of oral squamous cell carcinoma.

Authors:  Koji Yamamoto; Fumiki Yamashita; Makiko Kawaguchi; Aya Izumi; Takumi Kiwaki; Hiroaki Kataoka; Takeshi Kaneuji; Yoshihiro Yamashita; Tsuyoshi Fukushima
Journal:  Hum Cell       Date:  2021-07-11       Impact factor: 4.174

6.  A novel ferroptosis related gene signature is associated with prognosis in patients with ovarian serous cystadenocarcinoma.

Authors:  Zhixiang Yu; Haiyan He; Yanan Chen; Qiuhe Ji; Min Sun
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

7.  MIR29A Impedes Metastatic Behaviors in Hepatocellular Carcinoma via Targeting LOX, LOXL2, and VEGFA.

Authors:  Ya-Ling Yang; Ming-Chao Tsai; Yen-Hsiang Chang; Chen-Chen Wang; Pei-Yi Chu; Hung-Yu Lin; Ying-Hsien Huang
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

8.  The Orphan Nuclear Receptor Gene NR0B2 Is a Favorite Prognosis Factor Modulated by Multiple Cellular Signal Pathways in Human Liver Cancers.

Authors:  Runzhi Zhu; Yanjie Tu; Jingxia Chang; Haixia Xu; Jean C Li; Wang Liu; Ahn-Dao Do; Yuxia Zhang; Jinhu Wang; Benyi Li
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

Review 9.  Musashi-1-A Stemness RBP for Cancer Therapy?

Authors:  Nadine Bley; Ali Hmedat; Simon Müller; Robin Rolnik; Alexander Rausch; Marcell Lederer; Stefan Hüttelmaier
Journal:  Biology (Basel)       Date:  2021-05-05

10.  TMEM229A suppresses non‑small cell lung cancer progression via inactivating the ERK pathway.

Authors:  Xilin Zhang; Ying He; Yan Jiang; Ying Bao; Qiuqiang Chen; Dong Xie; Huanming Yu; Xiang Wang
Journal:  Oncol Rep       Date:  2021-06-29       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.